Randomised trial of the P2X₃receptor antagonist sivopixant for refractory chronic cough

Abstract

Sivopixant reduced objective cough frequency and improved health-related quality of life, with a low incidence of taste disturbance, among patients with refractory or unexplained chronic cough.